SLC29A2 Knockout Cell Line (HCT 116)

The choice depends on whether you are studying SLC29A2 (ENT2)'s role as an equilibrative nucleoside transporter or its contributions to nucleoside analog drug uptake. The Knockout line is the standard tool for asking whether ENT2 is required for nucleoside transport — ENT2 is broadly expressed and transports both purine and pyrimidine nucleosides as well as nucleobases. Overexpression is useful for testing nucleoside analog drug uptake or for distinguishing ENT2-specific functions from ENT1 (SLC29A1). For ENT2 research, the EDITGENE Knockout in HCT 116 is particularly relevant for studying nucleoside analog chemotherapy uptake (cytarabine/Ara-C, gemcitabine, fludarabine, cladribine) in a cancer cell context. ENT1 paralog expression analysis is important given functional overlap. ENT inhibitors (dipyridamole, NBMPR) specificity testing benefits from this knockout. Rescue with wild-type or transport-deficient ENT2 enables structure-function studies.

Primary applications: • Nucleoside analog drug sensitivity: cytarabine, gemcitabine, fludarabine, and cladribine dose-response analysis in ENT2-null versus rescued cells. • Nucleoside/nucleobase uptake: ³H-thymidine, ³H-uridine, ³H-adenine uptake assays to characterize ENT2 substrate scope. • ENT family paralog studies: SLC29A1 (ENT1) expression analysis to interpret ENT2-specific functions given substantial functional overlap. • ENT inhibitor specificity: dipyridamole and NBMPR (nitrobenzylmercaptopurine riboside) specificity testing with the knockout as genetic control. EDITGENE recommends this model for researchers investigating equilibrative nucleoside transport, nucleoside analog chemotherapy mechanisms, and ENT-targeted pharmacology.

Yes. ENT2 rescue experiments are well-established for nucleoside transporter research: • Construct design: use a codon-modified SLC29A2 sequence with a small C-terminal tag (FLAG, HA). ENT2 has 11 transmembrane domains in the canonical ENT family architecture. • Transport-deficient rescue: substrate-binding pocket mutations enable structure-function studies. • Drug sensitivity rescue: nucleoside analog (cytarabine, gemcitabine) sensitivity restoration in ENT2-null cells confirms rescue functionality. • Functional readout: rescue should restore nucleoside uptake (³H-thymidine, ³H-uridine) and nucleoside analog drug sensitivity. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.